Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 4/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313538 | 0.91 | SYK (0.47) | FGFR1SYKCDK4CCND1CDK6 | |
| SCHEMBL12235687 | 0.85 | IGF1R (0.57) | SYKCDK4CCND1CDK6PDGFRB | |
| SCHEMBL3585653 | 0.83 | SYK (0.49) | FGFR1SYKCDK4CCND1TNK2 | |
| SCHEMBL3572092 | 0.83 | FGFR1 (0.59) | FGFR1SYKEGFRPLK1 | |
| SCHEMBL3571984 | 0.83 | SYK (0.48) | FGFR1SYKCDK4CCND1CDK6 | |
| SCHEMBL13313545 | 0.81 | FGFR1 (0.59) | FGFR1SYKEGFRPLK1 | |
| SCHEMBL13313555 | 0.81 | AURKB (0.44) | FGFR1SYKTNK2AURKAAURKB | |
| SCHEMBL578929 | 0.80 | AURKA (0.53) | SYKAURKAAURKB | |
| SCHEMBL578928 | 0.80 | AURKA (0.53) | SYKAURKAAURKB | |
| SCHEMBL13313549 | 0.80 | AURKB (0.48) | SYKEGFRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107304-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | FGFR1 12/4885SYK 926/4885CDK4 39/4885 |
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | FGFR1 268/4885SYK 2935/4885CDK4 34/4885 |
| US-20130289014-A1 | Combination therapy in treatment of oncological and fibrotic diseases | AURKB, AURKC, AURKA | FGFR1 12/4885SYK 926/4885CDK4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.